Kore Private Wealth’s PTC Therapeutics PTCT Stock Holding History

Kore Private Wealth’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$19K	–	642
2019 Q1	$19K	Buy	+500	New	+$16.8K	﹤0.01%	514

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Kore Private Wealth's PTCT Position: Q2 2019 in Review

Kore Private Wealth sold out of PTC Therapeutics (PTCT) in Q2 2019, closing a stake of 500 shares — an estimated $19K sold.

Kore Private Wealth first reported a position in PTCT in Q1 2019 and held it in 1 quarter. The position peaked at $19K in Q1 2019. 176 funds tracked by Wall St. Rank hold PTCT as of Q2 2019.

Kore Private Wealth reported no remaining PTC Therapeutics position as of Q2 2019 after selling out during the quarter.
Kore Private Wealth sold 500 PTC Therapeutics shares in Q2 2019, an estimated $19K.
Kore Private Wealth first reported a position in PTC Therapeutics in Q1 2019 and held it in 1 quarter.
Kore Private Wealth's PTC Therapeutics position peaked at $19K in Q1 2019.
176 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.